188
Views
4
CrossRef citations to date
0
Altmetric
Original Articles

The potency of selatogrel, a reversible antagonist of the P2Y12 receptor, is affected by calcium concentration

, , , &
Pages 147-156 | Received 17 Aug 2020, Accepted 15 Dec 2020, Published online: 11 Jan 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Martine Gehin, Robert F. Storey, Corine Bernaud & Jasper Dingemanse. (2023) Clinical pharmacology of selatogrel for self-administration by patients with suspected acute myocardial infarction. Expert Opinion on Drug Metabolism & Toxicology 19:10, pages 697-708.
Read now

Articles from other publishers (3)

Véronique Pons, Cédric Garcia, Naomi Tidten-Luksch, Aengus Mac Sweeney, Eva Caroff, Céline Galés & Markus A. Riederer. (2022) Inverse agonist efficacy of selatogrel blunts constitutive P2Y12 receptor signaling by inducing the inactive receptor conformation. Biochemical Pharmacology 206, pages 115291.
Crossref
Lydie Crescence, Markus Kramberg, Martine Baumann, Markus Rey, Sebastien Roux, Laurence Panicot-Dubois, Christophe Dubois & Markus A. Riederer. (2021) The P2Y12 Receptor Antagonist Selatogrel Dissolves Preformed Platelet Thrombi In Vivo. Journal of Clinical Medicine 10:22, pages 5349.
Crossref
Wen Su, Jie-Gao Zhu, Xue-Qiao Zhao, Hui Chen, Wei-Ping Li & Hong-Wei Li. (2021) Altered serum calcium homeostasis independently predicts mortality in patients with acute coronary syndrome: a retrospective observational cohort study. BMJ Open 11:11, pages e049957.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.